• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
LY2062430 (Alzheimer's disease) - Analysis and Forecasts to 2022 Product Image

LY2062430 (Alzheimer's disease) - Analysis and Forecasts to 2022

  • Published: April 2012
  • 35 pages
  • GlobalData

LY2062430 (Alzheimer’s disease) – Analysis and Forecasts to 2022

Summary

GlobalData’s pharmaceuticals report, “LY2062430 (Alzheimer’s disease) – Analysis and Forecasts to 2022” provides LY2062430 global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of LY2062430 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Alzheimer’s Disease
2.2 Symptoms
2.3 Alzheimer’s disease Market
2.4 Epidemiology
2.5 Etiology
2.5.1 Age
2.5.2 Family History
2.5.3 Genetics
2.6 Economic Impact of Alzheimer’s disease
2.7 GlobalData Report Guidance
3 Alzheimer’s disease: Market Characterization
3.1 Alzheimer’s disease Market
3.2 Alzheimer’s disease Market Forecasts and CAGR
3.3 Drivers and Barriers of Alzheimer’s Disease Therapeutics Market
3.3.1 Ageing Population
3.3.2 Patent Expiries
3.3.3 New Product Launches
3.3.4 High Unmet Need
4 Classification of Alzheimer’s disease
4.1 Stage 1 (Mild)
4.2 Stage 2 (Moderate)
4.3 Stage 3 (Severe)
5 Treatment for Alzheimer’s disease
5.1 Cognitive Symptoms
5.1.1 Cholinesterase Inhibitors (ChEIs)
5.1.2 NMDA antagonists
5.1.3 Other Pharmacotherapeutic Agents
5.2 Behavioural Symptoms and Mood Disorders
5.2.1 Non-pharmacological Approaches
5.2.2 Prescription Medicines
5.3 Next-generation Drugs
5.3.1 Disease Modifying Agents
5.3.2 Tau-directed Therapies
5.3.3 Other Therapies
6 LY2062430 (solanezumab)
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.4 Factors Affecting Sales of LY2062430
6.4.1 Satisfying Unmet Need
6.4.2 Uncertainty over the Approval
6.4.3 Affordability
6.4.4 Low Dosing Convenience
6.5 Drug Evaluation
6.5.1 Drug Risk Benefit Score
6.5.2 Intensity of Competition
6.6 Sales Estimates
6.6.1 Target Patient Pool for LY2062430
6.6.2 Dosing
6.6.3 Market Penetration
6.6.4 Annual Cost of Therapy
6.6.5 Global Sales Projections of LY2062430
7 Alzheimer’s Disease Market: Appendix
7.1 Market Definitions
7.2 List of Abberiviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to Take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

1.1 List of Tables
Table 1: Alzheimer’s disease, World, Major Pipeline Products in Phase III
Table 2: Mild Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 3: Moderate Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 4: Severe Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 5: Non-pharmacological Approaches for Behavioural Symptoms and Mood Disorders
Table 6: Experimental Disease Modifying Drugs in Phase III for Alzheimer’s disease
Table 7: Drug Risk Benefit Score of LY2062430
Table 8: LY2062430, Alzheimer’s disease , Global, Sales Forecasts ($m), 2013–2022
Table 9: LY2062430, Alzheimer’s disease , The US, Sales Forecasts ($m), 2013–2022
Table 10: LY2062430, Alzheimer’s disease , UK, Sales Forecasts ($m), 2013–2022
Table 11: LY2062430, Alzheimer’s disease, France, Sales Forecasts ($m), 2013–2022
Table 12: LY2062430, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2013–2022
Table 13: LY2062430, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2013–2022
Table 14: LY2062430, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2013–2022
Table 15: LY2062430, Alzheimer’s disease, Japan, Sales Forecasts ($m), 2013–2022

1.2 List of Figures
Figure 1: Brain Affected by Alzheimer’s disease
Figure 2: Estimated Lifetime Risks for Alzheimer’s by Age and Sex, The US
Figure 3: Estimated Number of Cases of Alzheimer’s Disease (million), The US
Figure 4: Changes in Selected Causes of Death, The US, 2000-2008
Figure 5: Alzheimer’s disease, Global, Market Size Forecasts ($bn), 2011–2022
Figure 6: Drug Model Diagram of LY2062430
Figure 7: LY2062430, Alzheimer’s disease, Global, Sales Forecasts ($m), 2013–2022
Figure 8: LY2062430, Alzheimer’s disease, The US, Sales Forecasts ($m), 2013–2022
Figure 9: LY2062430, Alzheimer’s disease, UK, Sales Forecasts ($m), 2013–2022
Figure 10: LY2062430, Alzheimer’s disease, France, Sales Forecasts ($m), 2013–2022
Figure 11: LY2062430, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2013–2022
Figure 12: LY2062430, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2013–2022
Figure 13: LY2062430, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2013–2022
Figure 14: LY2062430, Alzheimer’s disease, Japan, Sales Forecasts ($m), 2013–2022
Figure 15: LY2062430, Global, Sales Distribution, 2022
Figure 16: Patients Approved for the Drug

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos